brexucabtagene autoleucel
gilead
['leukemia', 'brexu-cel']
brexu-cel elicited high rates of complete remission s/ mrd negativity in real-world patients w/ r/r b-cell acute lymphoblastic leukemia who received the car t-cell product as post-approval, standard-of-care treatment. #asco23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.